Immunic (IMUX) said Wednesday that interim data from a phase 2 trial show the potential effectiveness of its experimental drug vidofludimus calcium in progressive multiple sclerosis.
The company said the investigational drug was found to reduce neurofilament light chain levels compared with placebo in the study.
The company also said antiviral data suggested that the drug may reduce fatigue while preclinical data indicated that vidofludimus calcium promotes neuronal survival through the activation of nuclear receptor related 1, or Nurr1, and pathogenic T cell data support the drug's anti-inflammatory effects.
The data will be presented this week at a conference in Copenhagen, Denmark, Immunic said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.